Trial | NCT04468009  Report issue

Official Title

Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    134
This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
This study aims to use convalescent plasma as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit. Donors must have anti-SARS CoV2 antibodies. Recipients must be critically ill Covid-19 patients on mechanical ventilation.
Study Started
Jun 25
2020
Primary Completion
Jan 19
2021
Study Completion
Jun 19
2021
Last Update
Aug 25
2021

Biological Convalescent plasma

Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies

Standard of care No Intervention

Standard of care for Covid-19

PCC-19 Experimental

Treatment with convalescent plasma

Criteria 

Inclusion Criteria:

Age: 18 years or more.
Patient with Covid-19 confirmed with nuclear acid testing
Critically ill patients with Covid-19 on mechanical ventilation. Potencially critically ill patients (with acute respiratory distress syndrome, septic shock and/or multiple organ failure) with Covid-19.
Diagnosed with acute respiratory distress syndrome.
Informed consent.

Exclusion Criteria:

No consent.
Symptoms for a period longer than 20 days.
Not detectable by acid nuclear testing within 48 hours prior to elegibility.
Descompensated congestive heart failure, in which receiving 500ml of intrasvascular volume signifies a life risk.
History of severe adverse events or anaphylaxis to plasma components
No Results Posted